Exelixis Management

Management criteria checks 2/4

Exelixis' CEO is Mike Morrissey, appointed in Jul 2010, has a tenure of 12.33 years. total yearly compensation is $7.53M, comprised of 14.5% salary and 85.5% bonuses, including company stock and options. directly owns 0.4% of the company’s shares, worth €21.34M. The average tenure of the management team and the board of directors is 7.3 years and 18 years respectively.

Key information

Mike Morrissey

Chief executive officer

US$7.5m

Total compensation

CEO salary percentage	14.5%
CEO tenure	12.3yrs
CEO ownership	0.4%
Management average tenure	7.3yrs
Board average tenure	18yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mike Morrissey's remuneration changed compared to Exelixis's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2022	n/a	n/a	US$308m
Jun 30 2022	n/a	n/a	US$273m
Mar 31 2022	n/a	n/a	US$298m
Dec 31 2021	US$8m	US$1m	US$231m
Sep 30 2021	n/a	n/a	US$164m
Jun 30 2021	n/a	n/a	US$94m
Mar 31 2021	n/a	n/a	US$65m
Dec 31 2020	n/a	n/a	US$112m
Sep 30 2020	n/a	n/a	US$152m
Jun 30 2020	n/a	n/a	US$282m
Mar 31 2020	n/a	n/a	US$294m
Dec 31 2019	n/a	n/a	US$321m
Sep 30 2019	n/a	n/a	US$612m
Jun 30 2019	n/a	n/a	US$642m
Mar 31 2019	n/a	n/a	US$650m
Dec 31 2018	n/a	n/a	US$690m
Sep 30 2018	n/a	n/a	US$368m
Jun 30 2018	n/a	n/a	US$323m
Mar 31 2018	n/a	n/a	US$253m
Dec 31 2017	n/a	n/a	US$154m
Sep 30 2017	n/a	n/a	US$150m
Jun 30 2017	n/a	n/a	US$58m
Mar 31 2017	n/a	n/a	US$6m
Dec 31 2016	n/a	n/a	-US$70m
Sep 30 2016	n/a	n/a	-US$147m
Jun 30 2016	n/a	n/a	-US$181m
Mar 31 2016	n/a	n/a	-US$186m

Compensation vs Market: Mike's total compensation ($USD7.53M) is above average for companies of similar size in the German market ($USD2.61M).

Compensation vs Earnings: Mike's compensation has increased by more than 20% in the past year.

CEO

Mike Morrissey (61 yo)

12.3yrs

Tenure

US$7,530,431

Compensation

Dr. Michael M. Morrissey, Ph D., also known as Mike, serves as Independent Director at XW Laboratories Inc. Dr. Morrissey serves as Independent Chairman of the Board at Vera Therapeutics, Inc since May 24...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Stelios Papadopoulos	Co-Founder & Independent Chair of the Board	27.9yrs	US$467.21k	0.38% $ 20.1m
Michael Morrissey	CEO, President & Director	12.3yrs	US$7.53m	0.40% $ 21.3m
Christopher Senner	Executive VP & CFO	7.3yrs	US$2.46m	0.11% $ 5.8m
Peter Lamb	Executive VP of Scientific Strategy & Chief Scientific Officer	15.8yrs	US$1.96m	0.093% $ 4.9m
Jeffrey Hessekiel	Executive VP	8.8yrs	US$2.17m	0.15% $ 7.9m
Patrick Haley	Executive Vice President of Commercial	5.9yrs	US$2.12m	0.040% $ 2.1m
Dana Aftab	Executive Vice President of Business Operations	6.8yrs	no data	no data
Susan Hubbard	Executive Vice President of Public Affairs & Investor Relations	5.9yrs	no data	no data
Gregg Bernier	Vice President of Marketing	7.2yrs	no data	no data
Laura Dillard	Executive Vice President of Human Resources	8yrs	no data	no data
Anne Champsaur	Senior Vice President of Drug Safety	7.6yrs	no data	no data
William Berg	Senior Vice President of Medical Affairs	7.2yrs	no data	no data

7.3yrs

Average Tenure

57.5yo

Average Age

Experienced Management: EX9's management team is seasoned and experienced (7.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Stelios Papadopoulos	Co-Founder & Independent Chair of the Board	27.9yrs	US$467.21k	0.38% $ 20.1m
Michael Morrissey	CEO, President & Director	12.3yrs	US$7.53m	0.40% $ 21.3m
Jack Wyszomierski	Independent Director	18.8yrs	US$441.26k	0.085% $ 4.5m
George Poste	Independent Director	18.3yrs	US$439.21k	0.054% $ 2.9m
Lance Willsey	Independent Director	25.6yrs	US$425.12k	0.13% $ 7.0m
Vincent Marchesi	Independent Director	21.5yrs	US$435.26k	0.023% $ 1.2m
Alan Garber	Independent Director	17.8yrs	US$423.12k	0.0097% $ 517.2k
Carl Feldbaum	Independent Director	15.8yrs	US$423.12k	0.0026% $ 140.2k
Charles Sawyers	Member of the Scientific Advisory Board	no data	no data	no data
Ronald Evans	Member of the Scientific Advisory Board	no data	no data	no data
Julie Smith	Independent Director	6.2yrs	US$449.21k	0.0050% $ 268.2k
Maria Freire	Independent Director	4.6yrs	US$426.26k	0.012% $ 660.6k

18.0yrs

Average Tenure

66yo

Average Age

Experienced Board: EX9's board of directors are seasoned and experienced ( 18 years average tenure).

Exelixis Management

Management criteria checks 2/4

Key information

Recent management updates

Exelixis, Inc., Annual General Meeting, May 30, 2024

Exelixis, Inc. Announces Vicki L. Goodman Concludes Her Service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

Exelixis, Inc. Elects Dave Johnson to its Board of Directors

Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors

Exelixis, Inc. Announces Board Appointments

Executive Vice President of Commercial recently sold €320k worth of stock

Recent updates

Exelixis, Inc. Reaffirms Earnings Guidance for the Year 2024

Exelixis, Inc., Annual General Meeting, May 30, 2024

Exelixis, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Exelixis, Inc. Provides Earnings Guidance for the for Fiscal Year 2024

Exelixis, Inc. Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024

Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib)

Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares.

Exelixis Announces Initiation of the Stellar-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer

Exelixis, Inc. Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023

Exelixis, Inc. Announces Detailed Results from Phase 3 Cabinet Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023

Exelixis, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Exelixis, Inc. Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

Exelixis, Inc. Announces Vicki L. Goodman Concludes Her Service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer

Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Exelixis, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Exelixis, Inc. Elects Dave Johnson to its Board of Directors

Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors

Bristol-Myers Squibb Company and Exelixis, Inc. Announces Opdivo in Combination with Cabometyx Shows Durable Survival with over Three Years of Follow-Up in the Checkmate -9Er Trial in First-Line Advanced Renal Cell Carcinoma

Exelixis, Inc. and Sairopa B.V. Announces US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors

Exelixis, Inc. Provides Revenue Guidance for Fiscal Year 2023

Exelixis, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Exelixis, Inc. Provides Revenue Guidance for Full Year 2023

Exelixis, Inc. Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer

Exelixis, Inc. Announces Board Appointments

Exelixis, Inc. Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy

Exelixis, Inc. Announces Initial Dose-Escalation Results from the First-In-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022

Exelixis, Inc. Provides Revenue Guidance for 2022

Exelixis, Inc. Announces Promising Initial Dose-Escalation Results from the First-In-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022

Exelixis, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Exelixis, Inc. Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022

Exelixis, Inc. Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022

Second quarter 2022 earnings released: EPS: US$0.22 (vs US$0.31 in 2Q 2021)

Exelixis, Inc. Maintains Earnings Guidance for the Fiscal Year 2022

Exelixis, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Exelixis, Inc. Announces COSMIC-313 Met Its Primary Endpoint

Investor sentiment improved over the past week

Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer

Executive Vice President of Commercial recently sold €320k worth of stock

Exelixis, Inc. Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients

Investor sentiment deteriorated over the past week

Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2022

First quarter 2022 earnings released: EPS: US$0.21 (vs US$0.005 in 1Q 2021)

Insufficient new directors

Exelixis, Inc. Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma

Exelixis, Inc. Announces Charles Cohen to Retire from Board of Directors

Co-Founder & Independent Chairman recently sold €1.5m worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Exelixis, Inc. Provides Earnings Guidance for the Year 2022

Bristol Myers Squibb and Exelixis, Inc. Announces Two-Year Follow-Up Results from Analyses of the Phase 3 CheckMate -9ER Trial

Exelixis, Inc. Provides Sales Guidance for the Year 2022

Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022

Exelixis, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2021; Revenue Guidance for the Full Year 2022

Exelixis, Inc. Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma

Exelixis, Inc. Announces Initiation of Phase 1B Trial Evaluating XL092 in Combination with Immuno-Oncology Therapies in Patients with Advanced Solid Tumors

Executive Vice President of Commercial recently sold €266k worth of stock

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS US$0.12 (vs US$0.10 loss in 3Q 2020)

Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021

Exelixis, Inc. Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021

Senior Vice President of Sales Jonathan Berndt has left the company

Exelixis, Inc. Announces Partner Takeda Pharmaceutical Company Limited and Ono Receive Approval in Japan for CABOMETYX in Combination with Opdivo for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma

Second quarter 2021 earnings released: EPS US$0.31 (vs US$0.22 in 2Q 2020)

Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021

Exelixis, Inc. Announces Positive Phase 2 Results for Cabometyx (Cabozantinib) in Combination with Opdivo (Nivolumab) in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma At Asco 2021

Exelixis, Inc. Announces Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer

Independent Director recently sold €839k worth of stock